Literature DB >> 2989400

Isolation and characterization of cDNA clones corresponding to two different human apoC-III alleles.

S K Karathanasis, V I Zannis, J L Breslow.   

Abstract

We have recently reported that the human apolipoprotein A-I (apoA-I) and apolipoprotein C-III (apoC-III) genes are physically linked and that the presence of a DNA insertion in the apoA-I gene is correlated with apoA-I-apoC-III deficiency in patients with premature atherosclerosis. In addition, the presence of a polymorphic restriction endonuclease site (SacI) in the 3' noncoding region of apoC-III mRNA has been correlated with hypertriglyceridemia in humans. In this study, we report the isolation and characterization of cDNA clones containing the entire apoC-III mRNA coding sequence. The nucleotide-derived apoC-III amino acid sequence indicates that the apoC-III primary translational product contains a 20 amino acid N-terminal extension, which conforms with the general properties of known signal peptides, and is highly homologous to the recently reported rat apoC-III signal peptide. The DNA-derived apoC-III amino acid sequence differs from the previously reported apoC-III amino acid sequence at four amino acid residues. More specifically, at positions +32, +33, +37, +39, the DNA sequence predicts Glu, Ser, Gln, Ala, respectively, while the previously reported sequence specifies Ser, Gln, Ala, Gln, respectively. Finally, isolation and characterization of apoC-III cDNA clones, with or without the polymorphic SacI restriction site, indicated that the apoC-III nucleotide sequence corresponding to the Sac+ and Sac- clones differs at three nucleotide sites; however, the amino acid sequence specified by the Sac+ and Sac- alleles is identical.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2989400

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  8 in total

1.  Detection of SstI restriction site polymorphism in human APOC3 by the polymerase chain reaction.

Authors:  J E Hixson; D T Vernier; P K Powers
Journal:  Nucleic Acids Res       Date:  1991-01-11       Impact factor: 16.971

2.  Increased expression of apolipoprotein genes accompanies differentiation in the intestinal cell line Caco-2.

Authors:  S R Reisher; T E Hughes; J M Ordovas; E J Schaefer; S I Feinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

3.  Mapping of the human APOB gene to chromosome 2p and demonstration of a two-allele restriction fragment length polymorphism.

Authors:  L S Huang; D A Miller; G A Bruns; J L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

4.  Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia.

Authors:  A von Eckardstein; H Holz; M Sandkamp; W Weng; H Funke; G Assmann
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

5.  Patterns of association between genetic variability in apolipoprotein (apo) B, apo AI-CIII-AIV, and cholesterol ester transfer protein gene regions and quantitative variation in lipid and lipoprotein traits: influence of gender and exogenous hormones.

Authors:  A Kessling; S Ouellette; O Bouffard; A Chamberland; C Bétard; E Selinger; M Xhignesse; S Lussier-Cacan; J Davignon
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

6.  Association between coronary heart disease and the apolipoprotein A-I/C-III/A-IV complex in a Japanese population.

Authors:  H Bai; K Saku; R Liu; M Imamura; K Arakawa
Journal:  Hum Genet       Date:  1995-01       Impact factor: 4.132

7.  Extracoronary atherosclerosis and genetic variants of apolipoprotein AI-CIII cluster in myocardial infarction survivors from southern Italy.

Authors:  F De Lorenzo; A Monticelli; S Cocozza; B De Simone; P Rubba
Journal:  Clin Investig       Date:  1994-06

8.  Apolipoprotein multigene family: tandem organization of human apolipoprotein AI, CIII, and AIV genes.

Authors:  S K Karathanasis
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.